Intensity of immune/clotting assays relate to multiple antiphospholipid antibody positivity in thrombotic primary antiphospholipid syndrome.
Antiphospholipid
Dual and triple positivity
Lupus anticoagulant
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
10
06
2020
accepted:
16
09
2020
revised:
06
09
2020
pubmed:
9
10
2020
medline:
22
6
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
The dual positivity (DP) and triple positivity (TP) concepts bypass the poor comparability of immune/clotting assay for the laboratory classification of antiphospholipid syndrome (APS). To evaluate intensity of immune/clotting assays and DP/TP through different clinical severity groups (CSG) as follows: (1) non-thrombotic asymptomatic carriers of aPL (N-THR), thrombotic primary APS (THR), deceased (D) for recurrent and fatal thrombosis. Activated partial thromboplastin time ratio (aPTTr), dilute Russell viper venom time ratio (DRVVTr), IgG/IgM anticardiolipin (aCL) and anti β-2-glycoprotein-I (aβ2GPI). Participants: 33 N-THR, 64 THR and 11 D. The frequency of DP and TP (DRVVTr or aPTTr partnered with respective IgG aCL or aβ2GPI) increased across CSG (p = 0.006 and p = 0.003); mean DRVVTr and IgG aCL/aβ2GPI were always greater in TP versus non-TP within each CSG and progressively increased across the CSG. The intensity of individual lupus anticoagulants partnered with their corresponding IgG aPL related to the frequency of multiple positivity throughout CSG suggesting that of intensity of immune/clotting assays and multiple positivity are the different faces of the same diagnostic coin in our thrombotic PAPS cohort.
Identifiants
pubmed: 33030632
doi: 10.1007/s12185-020-03009-2
pii: 10.1007/s12185-020-03009-2
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Biomarkers
0
Immunoglobulin G
0
Immunoglobulin M
0
Lupus Coagulation Inhibitor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-189Références
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.
doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J ThrombHaemost. 2006;4:295–306.
doi: 10.1111/j.1538-7836.2006.01753.x
Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. ThrombHaemost. 2005;93:1147–52.
Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A, et al. Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-β2-glycoprotein I activity. Thromb Res. 2007;120:127–33.
doi: 10.1016/j.thromres.2006.07.014
Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. Subcommittee on Lupus anticoagulant/phospholipid/dependent antibodies testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J ThrombHaemost. 2014;12:792–5.
doi: 10.1111/jth.12537
Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. J ThrombHaemost. 2009;7:1737–40.
doi: 10.1111/j.1538-7836.2009.03555.x
Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the standardisation of the antiphospholipid antibodies. Lupus. 2009;18:913–9.
doi: 10.1177/0961203309106919
Pengo V, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. DRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta-2-glycoprotein I autoantibodies. ThrombHaemost. 1999;81:256–8.
Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol. 2006;33:1775–9.
pubmed: 16960938
Martinez AP, Cunningham MT. Antiphospholipid syndrome: analysis of dilute Russell’s viper venom time titer. Blood Coagul Fibrinolysis. 2016;27:557–62.
doi: 10.1097/MBC.0000000000000550
Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG/IgMantiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J ThrombHaemost. 2016;14:1530–48.
doi: 10.1111/jth.13379
Yelnik CM, Urbanski G, Drumez E, Sobanski V, Maillard H, Lanteri A, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2016;26:163–9.
doi: 10.1177/0961203316657433
Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J ThrombHaemost. 2010;8:237–42.
doi: 10.1111/j.1538-7836.2009.03674.x
Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum. 2012;64:1–10.
doi: 10.1002/art.33349
Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med. 1996;100:530–6.
doi: 10.1016/S0002-9343(96)00060-5
Froom P, Saffuri-Elias E, Rozenberg O, Barak M. The association of serum antiphospholipid antibodies and dilute Russell's viper venom times. J ClinPathol. 2014;67:441–4.
Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus. 2010;19:440–5.
doi: 10.1177/0961203310361356
Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504–12.
doi: 10.1002/art.33340
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the global anti-phospholipid syndrome score. Rheumatology. 2013;52:1397–403.
doi: 10.1093/rheumatology/kes388
Forastiero R. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus. 2014;23:1252–4.
doi: 10.1177/0961203314531635
Pengo V, Del Ross T, Ruffatti A, Bison E, Cattini MG, Pontara E, et al. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thromb Res. 2018;172:172–8.
doi: 10.1016/j.thromres.2018.11.003
Chayoua W, Kelchtermans H, Gris JC, Moore GW, Musiał J, Wahl D, et al. The (non-) sense of detecting anti-cardiolipin and anti-β2glycoprotein-I IgM antibodies in the antiphospholipid syndrome. J ThrombHaemost. 2020;18:169–79.
doi: 10.1111/jth.14633